Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group

Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at The Goldman Sachs Group to a “strong-buy” rating in a report issued on Monday,Zacks.com reports.

Other research analysts also recently issued research reports about the stock. Needham & Company LLC increased their price target on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, March 17th. Chardan Capital restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Wednesday, March 18th. Wall Street Zen lowered Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Canaccord Genuity Group lifted their target price on Stoke Therapeutics from $36.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Finally, Wedbush boosted their target price on Stoke Therapeutics from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Stoke Therapeutics Stock Down 6.1%

STOK stock opened at $29.46 on Monday. Stoke Therapeutics has a 52 week low of $11.66 and a 52 week high of $40.22. The firm has a market capitalization of $1.83 billion, a P/E ratio of -10.48 and a beta of 1.17. The company has a fifty day simple moving average of $30.98 and a two-hundred day simple moving average of $32.33.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. Stoke Therapeutics had a negative net margin of 529.20% and a negative return on equity of 48.84%. The firm had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.48 million. As a group, analysts anticipate that Stoke Therapeutics will post -3.22 EPS for the current year.

Insider Transactions at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 1,457 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total transaction of $43,637.15. Following the transaction, the general counsel directly owned 18,086 shares in the company, valued at approximately $541,675.70. This represents a 7.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 1,795 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the sale, the insider directly owned 34,826 shares in the company, valued at $1,064,979.08. This trade represents a 4.90% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 9.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of STOK. Tema ETFs LLC boosted its position in shares of Stoke Therapeutics by 16.1% during the second quarter. Tema ETFs LLC now owns 9,917 shares of the company’s stock valued at $324,000 after buying an additional 1,377 shares during the period. Generali Investments Management Co LLC raised its holdings in shares of Stoke Therapeutics by 379.6% in the second quarter. Generali Investments Management Co LLC now owns 33,149 shares of the company’s stock worth $1,085,000 after buying an additional 26,237 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Stoke Therapeutics by 24.4% in the second quarter. Assenagon Asset Management S.A. now owns 1,128,388 shares of the company’s stock worth $36,921,000 after buying an additional 221,373 shares during the period. Versant Capital Management Inc lifted its stake in shares of Stoke Therapeutics by 22.6% during the 2nd quarter. Versant Capital Management Inc now owns 1,951 shares of the company’s stock worth $64,000 after acquiring an additional 359 shares during the last quarter. Finally, Western Wealth Management LLC bought a new stake in shares of Stoke Therapeutics during the 1st quarter worth approximately $55,000.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.